Invion has closed recruitment for its Phase 1 trial in non-melanoma skin cancer, reporting a 79% disease control rate across 14 treated patients.

The figure anchors the company's announcement on the study, which tested its investigational therapy in a small first-in-human cohort. A 79% disease control rate means the majority of patients saw their disease held in check — a milestone for any Phase 1 oncology program, where safety and tolerability typically come first and efficacy signals are exploratory.

What do we know about the trial?

The basics the company has confirmed:

• Design: Phase 1, the earliest stage of human testing.
• Indication: non-melanoma skin cancer, a broad category that includes basal cell carcinoma and squamous cell carcinoma.
• Cohort: 14 patients.
• Headline result: 79% disease control rate.
• Status: recruitment now closed.

Phase 1 trials of this size can't confirm efficacy. They establish safety, dosing and — when investigators are lucky — early signals worth chasing into larger, controlled studies. A disease control rate, unlike a response rate, includes patients whose disease stabilized rather than shrank, so it sets a lower bar than complete or partial response data.

Why the cohort size matters

Fourteen patients is a small sample, and the 79% figure carries wide statistical uncertainty at that scale. Even so, dermatologic oncology watchers pay attention to disease control in non-melanoma skin cancer because the field's treatment arsenal for advanced disease remains thin. Most non-melanoma skin cancers are cured with surgery or localized therapy; the unmet need concentrates in patients whose tumors recur, metastasize or can't be operated on.

Invion now moves to the next question any Phase 1 program faces: whether the data support expansion into later-stage trials with larger cohorts and harder endpoints, such as objective response rate or progression-free survival.

What's next for the program?

With recruitment closed, attention shifts to full data readout. Companies typically use closed Phase 1 cohorts to lock dosing, finalize the safety profile and decide whether to advance to Phase 2. For Invion, that means presenting complete results from the 14 patients — including how investigators measured disease control and over what follow-up period.

Non-melanoma skin cancer is the most common cancer worldwide, and new systemic options would compete against established treatments including hedgehog pathway inhibitors and PD-1 blockade for advanced cases. Whether Invion's candidate can carve out a place depends on data the company hasn't yet published in full.

The closed trial sets up the next readout as the program's real test.